Prime medicine reports first quarter 2023 financial results and provides business updates

-- new data further demonstrating ability of prime editing to correct causative mutation of cgd and highlighting potential of passige platform to multiplex edit car-t cells to be presented at asgct annual meeting -- -- expanded board of directors with appointment of jeff marrazzo, former ceo of spark therapeutics --
PRME Ratings Summary
PRME Quant Ranking